A rodent model of premenstrual dysphoria: Progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants

Behavioural Brain Research

Volumn 234, Issue 2, 2012, Pages 238-247

  Li, Yan ^a   Pehrson, Alan L ^a   Budac, David P ^a   Sánchez, Connie ^a   Gulinello, Maria ^b  

^a LUNDBECK RESEARCH USA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Amitriptyline; Anhedonia; Antidepressant; Depression; Duloxetine; Female; Fluoxetine; Forced swim; Premenstrual dysphoria; Progesterone withdrawal; Rat; Social preference

Indexed keywords

AMITRIPTYLINE; DULOXETINE OXALATE; ESTRADIOL; ESTROGEN; FLUOXETINE; PROGESTERONE; SACCHARIN; SEROTONIN; TRYPTOPHAN;

AFFECT; AMINO ACID BLOOD LEVEL; ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; FEMALE; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILIZATION; NEGATIVE FEEDBACK; NOCICEPTION; NONHUMAN; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RAT; SEROTONIN BRAIN LEVEL; TEMPERATURE SENSITIVITY; TREATMENT DURATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; AUTORADIOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; FEMALE; FOOD PREFERENCES; HORMONES; MOOD DISORDERS; MOTOR ACTIVITY; NOCICEPTION; OVARIECTOMY; PREMENSTRUAL SYNDROME; PROGESTERONE; RATS; RATS, LONG-EVANS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SOCIAL BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME; SWIMMING; TRYPTOPHAN;

EID: 84864033696     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.06.034     Document Type: Article

References (113)

1. Dennerstein L., Lehert P., Bäckström T.C., Heinemann K. The effect of premenstrual symptoms on activities of daily life. Fertility and Sterility 2010, 94:1059-1064.
2. Hsiao C.C., Liu C.Y., Hsiao M.C. No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder. Psychiatry and Clinical Neurosciences 2004, 58:593-599.
3. Andréen L., Sundström-Poromaa I., Bixo M., Andersson A., Nyberg S., Bäckström T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 2005, 30:212-224.
4. Hammarbäck S., Bäckström T., Holst J., von Schoultz B., Lyrenäs S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstetricia et Gynecologica Scandinavica 1985, 64:393-397.
5. Segebladh B., Borgström A., Nyberg S., Bixo M., Sundström-Poromaa I. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. American Journal of Obstetrics and Gynecology 2009, 201:139 e1-1398.
6. Hammarbäck S. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstetricia et Gynecologica Scandinavica 1988, 67:159-166.
7. Zweifel J.E., O'Brien W.H. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997, 22:189-212.
8. Galea L.A., Wide J.K., Barr A.M. Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. Behavioural Brain Research 2001, 122:1-9.
9. Gulinello M., Gong Q.H., Smith S.S. Progesterone withdrawal increases the alpha4 subunit of the GABA(A) receptor in male rats in association with anxiety and altered pharmacology - a comparison with female rats. Neuropharmacology 2002, 43:701-714.
10. Gulinello M., Orman R., Smith S.S. Sex differences in anxiety, sensorimotor gating and expression of the alpha4 subunit of the GABAA receptor in the amygdala after progesterone withdrawal. European Journal of Neuroscience 2003, 17:641-648.
11. Beckley E.H., Finn D.A. Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility. Pharmacology Biochemistry and Behavior 2007, 87:412-419.
12. Costa A.M., Spence K.T. Smith SS, ffrench-Mullen JM. Withdrawal from the endogenous steroid progesterone results in GABAA currents insensitive to benzodiazepine modulation in rat CA1 hippocampus. Journal of Neurophysiology 1995, 74:464-469.
13. Follesa P., Concas A., Porcu P., Sanna E., Serra M., Mostallino M.C., et al. Role of allopregnanolone in regulation of GABA(A) receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Research. Brain Research Reviews 2001, 37:81-90.
14. Gallo M.A., Smith S.S. Progesterone withdrawal decreases latency to and increases duration of electrified prod burial: a possible rat model of PMS anxiety. Pharmacology Biochemistry and Behavior 1993, 46:897-904.
15. Gangisetty O., Reddy D.S. Neurosteroid withdrawal regulates GABA-A receptor alpha4-subunit expression and seizure susceptibility by activation of progesterone receptor-independent early growth response factor-3 pathway. Neuroscience 2010, 170:865-880.
16. Griffiths J., Lovick T. Withdrawal from progesterone increases expression of alpha4, beta1, and delta GABA(A) receptor subunits in neurons in the periaqueductal gray matter in female Wistar rats. Journal of Comparative Neurology 2005, 486:89-97.
17. Moran M.H., Goldberg M., Smith S.S. Progesterone withdrawal II: insensitivity to the sedative effects of a benzodiazepine. Brain Research 1998, 807:91-100.
18. Moran M.H., Smith S.S. Progesterone withdrawal I: pro-convulsant effects. Brain Research 1998, 807:84-90.
19. Reddy D.S., Kim H.Y., Rogawski M.A. Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia 2001, 42:328-336.
20. Smith S.S., Gong Q.H., Li X., Moran M.H., Bitran D., Frye C.A., et al. Withdrawal from 3alpha-OH-5alpha-pregnan-20-One using a pseudopregnancy model alters the kinetics of hippocampal GABAA-gated current and increases the GABAA receptor alpha4 subunit in association with increased anxiety. Journal of Neuroscience 1998, 18:5275-5284.
21. Bitran D., Smith S.S. Termination of pseudopregnancy in the rat produces an anxiogenic-like response that is associated with an increase in benzodiazepine receptor binding density and a decrease in GABA-stimulated chloride influx in the hippocampus. Brain Research Bulletin 2005, 64:511-518.
22. Epperson C.N., Pittman B., Czarkowski K.A., Stiklus S., Krystal J.H., Grillon C. Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology 2007, 32:2190-2198.
23. Smith S.S. Withdrawal properties of a neuroactive steroid: implications for GABA(A) receptor gene regulation in the brain and anxiety behavior. Steroids 2002, 67:519-528.
24. Galeeva A.Y., Tuohimaa P., Shalyapina V.G. The role of sex steroids in forming anxiety states in female mice. Neuroscience and Behavioral Physiology 2003, 33:415-420.
25. Kask K., Gulinello M., Bäckström T., Geyer M.A., Sundström-Poromaa I. Patients with premenstrual dysphoric disorder have increased startle response across both cycle phases and lower levels of prepulse inhibition during the late luteal phase of the menstrual cycle. Neuropsychopharmacology 2008, 33:2283-2290.
26. Hsu F.C., Smith S.S. Progesterone withdrawal reduces paired-pulse inhibition in rat hippocampus: dependence on GABA(A) receptor alpha4 subunit upregulation. Journal of Neurophysiology 2003, 89:186-198.
27. Biggio G., Follesa P., Sanna E., Purdy R.H., Concas A. GABAA-receptor plasticity during long-term exposure to and withdrawal from progesterone. International Review of Neurobiology 2001, 46:207-241.
28. Amital D., Herskovitz C., Fostick L., Silberman A., Doron Y., Zohar J., et al. The premenstrual syndrome and fibromyalgia--similarities and common features. Clinical Reviews in Allergy and Immunology 2010, 38:107-115.
29. Kuczmierczyk A.R., Adams H.E., Calhoun K.S., Naor S., Giombetti R., Cattalani M., et al. Pain responsivity in women with premenstrual syndrome across the menstrual cycle. Perceptual and Motor Skills 1986, 63:387-393.
30. Saavedra M., Contreras C.M., Azamar-Arizmendi G., Hernandez-Lozano M. Differential progesterone effects on defensive burying and forced swimming tests depending upon a gradual decrease or an abrupt suppression schedules. Pharmacology Biochemistry and Behavior 2006, 83:130-135.
31. Cutler S.M., Vanlandingham J.W., Stein D.G. Tapered progesterone withdrawal promotes long-term recovery following brain trauma. Experimental Neurology 2006, 200:378-385.
32. Suda S., Segi-Nishida E., Newton S.S., Duman R.S. A postpartum model in rat: behavioral and gene expression changes induced by ovarian steroid deprivation. Biological Psychology 2008, 64:311-319.
33. Vanselow W., Dennerstein L., Greenwood K.M., de Lignieres B. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. Journal of Psychosomatic Obstetrics and Gynecology 1996, 17:29-38.
34. Doornbos B., Fokkema D.S., Molhoek M., Tanke M.A., Postema F., Korf J. Abrupt rather than gradual hormonal changes induce postpartum blues-like behavior in rats. Life Sciences 2009, 84:69-74.
35. Frye C.A., Bayon L.E. Cyclic withdrawal from endogenous and exogenous progesterone increases kainic acid and perforant pathway induced seizures. Pharmacology Biochemistry and Behavior 1999, 62:315-321.
36. Overstreet D.H., Knapp D.J., Breese G.R. Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Pharmacology Biochemistry and Behavior 2004, 77:405-413.
37. Becker H.C., Diaz-Granados J.L., Hale R.L. Exacerbation of ethanol withdrawal seizures in mice with a history of multiple withdrawal experience. Pharmacology Biochemistry and Behavior 1997, 57:179-183.
38. Lovick T.A., Devall A.J. Progesterone withdrawal-evoked plasticity of neural function in the female periaqueductal grey matter. Neural Plasticity 2009, 2009:730902.
39. Löfgren M., Johansson I.M., Meyerson B., Lundgren P., Bäckström T. Progesterone withdrawal effects in the open field test can be predicted by elevated plus maze performance. Hormones and Behavior 2006, 50:208-215.
40. Stoffel E.C., Craft R.M. Ovarian hormone withdrawal-induced " depression" in female rats. Physiology and Behavior 2004, 83:505-513.
41. Navarre B.M., Laggart J.D., Craft R.M. Anhedonia in postpartum rats. Physiology and Behavior 2010, 99:59-66.
42. Sundström Poromaa I., Smith S., Gulinello M. GABA receptors, progesterone and premenstrual dysphoric disorder. Archives of Women's Mental Health 2003, 6:23-41.
43. Concas A., Follesa P., Barbaccia M.L., Purdy R.H., Biggio G. Physiological modulation of GABA(A) receptor plasticity by progesterone metabolites. European Journal of Pharmacology 1999, 375:225-235.
44. Sundström I., Nyberg S., Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997, 17:370-381.
45. Kaur G., Kulkarni S.K. Evidence for serotonergic modulation of progesterone-induced hyperphagia, depression and algesia in female mice. Brain Research 2002, 943:206-215.
46. Ladisich W. Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes. Psychoneuroendocrinology 1977, 2:257-266.
47. Møller S.E., Beurs P., Timmerman L., Tan B.K., Leijnse-Ybema H.J., Cohen Stuart M.H., et al. Plasma tryptophan and tyrosine ratios to competing amino acids in relation to antidepressant response to citalopram and maprotiline. Psychopharmacology 1986, 88:96-100.
48. Rasgon N., McGuire M., Tanavoli S., Fairbanks L., Rapkin A. Neuroendocrine response to an intravenous l-tryptophan challenge in women with premenstrual syndrome. Fertility and Sterility 2000, 73:144-149.
49. Ashby C.R., Carr L.A., Cook C.L., Steptoe M.M., Franks D.D. Alteration of 5-HT uptake by plasma fractions in the premenstrual syndrome. Journal of Neural Transmission. General Section 1990, 79:41-50.
50. Maurer-Spurej E., Pittendreigh C., Misri S. Platelet serotonin levels support depression scores for women with postpartum depression. Journal of Psychiatry and Neuroscience 2007, 32:23-29.
51. Kohl C., Walch T., Huber R., Kemmler G., Neurauter G., Fuchs D., et al. Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues. Journal of Affective Disorders 2005, 86:135-142.
52. Maes M., Verkerk R., Bonaccorso S., Ombelet W., Bosmans E., Scharpé S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sciences 2002, 71:1837-1848.
53. Gereau R.W., Kedzie K.A., Renner K.J. Effect of progesterone on serotonin turnover in rats primed with estrogen implants into the ventromedial hypothalamus. Brain Research Bulletin 1993, 32:293-300.
54. Hackmann E., Wirz-Justice A., Lichtsteiner M. The uptake of dopamine and serotonin in rat brain during progesterone decline. Psychopharmacologia 1973, 32:183-191.
55. Benmansour S., Piotrowski J.P., Altamirano A.V., Frazer A. Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology 2009, 34:555-564.
56. Fernandez-Guasti A., Agrati D., Reyes R., Ferreira A. Ovarian steroids counteract serotonergic drugs actions in an animal model of obsessive-compulsive disorder. Psychoneuroendocrinology 2006, 31:924-934.
57. Van der Does A.J.W. The effects of tryptophan depletion on mood and psychiatric symptoms. Journal of Affective Disorders 2001, 64:107-119.
58. Menkes D.B., Coates D.C., Fawcett J.P. Acute tryptophan depletion aggravates premenstrual syndrome. Journal of Affective Disorders 1994, 32:37-44.
59. Klatzkin R.R., Lindgren M.E., Forneris C.A., Girdler S.S. Histories of major depression and premenstrual dysphoric disorder: evidence for phenotypic differences. Biological Psychology 2010, 84:235-247.
60. Craft R.M., Kostick M.L., Rogers J.A., White C.L., Tsutsui K.T. Forced swim test behavior in postpartum rats. Pharmacology Biochemistry and Behavior 2010, 96:402-412.
61. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
62. Shishkina G.T., Kalinina T.S., Dygalo N.N. Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect. Neuroscience 2007, 150:404-412.
63. Caldarone B.J., Karthigeyan K., Harrist A., Hunsberger J.G., Wittmack E., King S.L., et al. Sex differences in response to oral amitriptyline in three animal models of depression in C57BL/6J mice. Psychopharmacology 2003, 170:94-101.
64. Herman Z.S., Obuchowicz E., Kowalski J., Plech A. Leu-enkephalin content in rat brain during prolonged treatment with imipramine or amitriptyline. Neuropeptides 1986, 7:113-124.
65. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. European Journal of Pharmacology 1978, 47:379-391.
66. Strekalova T., Spanagel R., Bartsch D., Henn F.A., Gass P. Stress-induced anhedonia in mice is associated with deficits in forced swimming and exploration. Neuropsychopharmacology 2004, 29:2007-2017.
67. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Research 1996, 711:163-174.
68. Casarotto P.C., Andreatini R. Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone. European Neuropsychopharmacology 2007, 17:735-742.
69. D'Aquila P.S., Newton J., Willner P. Diurnal variation in the effect of chronic mild stress on sucrose intake and preference. Physiology and Behavior 1997, 62:421-426.
70. Muscat R., Willner P. Suppression of sucrose drinking by chronic mild unpredictable stress: a methodological analysis. Neuroscience and Biobehavioral Reviews 1992, 16:507-517.
71. Christianson J.P., Paul E.D., Irani M., Thompson B.M., Kubala K.H., Yirmiya R., et al. The role of prior stressor controllability and the dorsal raphe nucleus in sucrose preference and social exploration. Behavioural Brain Research 2008, 193:87-93.
72. Lukas M., Toth I., Reber S.O., Slattery D.A., Veenema A.H., Neumann I.D. The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology 2011, 36:2159-2168.
73. Tsuda M.C., Ogawa S. Long-lasting consequences of neonatal maternal separation on social behaviors in ovariectomized female mice. PLoS One 2012, 7:e33028.
74. Kaidanovich-Beilin O., Lipina T., Vukobradovic I., Roder J., Woodgett J.R. Assessment of social interaction behaviors. Journal of Visualized Experiments 2011, 48:e2473. 10.3791/2473.
75. Chung K.F., Tso K.C. Relationship between insomnia and pain in major depressive disorder: a sleep diary and actigraphy study. Sleep Medicine 2010, 11:752-758.
76. Marangell L.B., Clauw D.J., Choy E., Wang F., Shoemaker S., Bradley L., et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine. Pain 2011, 152:31-37.
77. Fillingim R.B., Edwards R.R. The association of hormone replacement therapy with experimental pain responses in postmenopausal women. Pain 2001, 92:229-234.
78. Aloisi A.M., Bonifazi M. Sex hormones, central nervous system and pain. Hormones and Behavior 2006, 50:1-7.
79. Hanstein R., Zhao J.B., Basak R., Smith D.N., Zuckerman Y.Y., Hanani M., et al. Focal inflammation causes carbenoxolone-sensitive tactile hypersensitivity in mice. Open Pain Journal 2010, 3:123-133.
80. Pamplona F.A., Pandolfo P., Duarte F.S., Takahashi R.N., Prediger R.D. Altered emotionality leads to increased pain tolerance in amyloid beta (Abeta1-40) peptide-treated mice. Behavioural Brain Research 2010, 212:96-102.
81. Schreiber S., Pick C.G. From selective to highly selective SSRIs: a comparison of the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram. European Neuropsychopharmacology 2006, 16:464-468.
82. Jones C.K. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. Journal of Pharmacology and Experimental Therapeutics 2005, 312:726-732.
83. Pehrson A.L., Cremers T., Betry C., van der Hart M.G., Jorgensen L., Madsen M., et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. European Neuropsychopharmacology 2012, http://dx.doi.org/10.1016/j.euroneuro.2012.04.006.
84. Mørk A., Pehrson A., Brennum L.T., Nielsen S.M., Zhong H., Lassen A.B., et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. Journal of Pharmacology and Experimental Therapeutics 2012, 340:666-675.
85. Zhao J., Gao P., Zhu D. Optimization of Zn2+containing mobile phase for simultaneous determination of kynurenine, kynurenic acid and tryptophan in human plasma by high performance liquid chromatography. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2010, 878:603-608.
86. Miller C.L., Llenos I.C., Cwik M., Walkup J., Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochemistry International 2008, 52:1297-1303.
87. Kehr J. Monitoring chemistry of brain microenvironment: biosensors, microdialysis and related techniques. Modern techniques in neuroscience research 1999, 1149-1198. Springer-Verlag GmbH, Heidelberg, Chapter 41. U. Windhorst, H. Johansson (Eds.).
88. Kehr J., Yoshitake T. Monitoring brain chemical signals by microdialysis. Encyclopedia of sensors 2006, 287-312. American Scientific Publishers, USA. C.A. Grimes, E.C. Dickey, M.V. Pishko (Eds.).
89. Harris A.C., Hanes S.L., Gewirtz J.C. Potentiated startle and hyperalgesia during withdrawal from acute morphine: effects of multiple opiate exposures. Psychopharmacology 2004, 176:266-273.
90. Smith S.S., Gong Q.H., Hsu F.C. Markowitz RS, ffrench-Mullen JM, Li X. GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 1998, 392:926-930.
91. Renner K.J., Krey L.C., Luine V.N. Effect of progesterone on monoamine turnover in the brain of the estrogen-primed rat. Brain Research Bulletin 1987, 19:195-202.
92. González-Flores O., Gómora-Arrati P., García-Juárez M., Miranda-Martínez A., Armengual-Villegas A., Camacho-Arroyo I., et al. Progesterone receptor isoforms differentially regulate the expression of tryptophan and tyrosine hydroxylase and glutamic acid decarboxylase in the rat hypothalamus. Neurochemistry International 2011, 59:671-676.
93. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neuroscience and Biobehavioral Reviews 2005, 29:547-569.
94. Ho H.P., Olsson M., Westberg L., Melke J., Eriksson E. The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability?. Neuropsychopharmacology 2001, 24:502-510.
95. Kasamo K., Blier P., De Montigny C. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. Journal of Pharmacology and Experimental Therapeutics 1996, 277:278-286.
96. Katoh A., Eigyo M., Ishibashi C., Naitoh Y., Takeuchi M., Ibii N., et al. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. Journal of Pharmacology and Experimental Therapeutics 1995, 272:1067-1075.
97. Reneric J.P., Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology 1998, 136:190-197.
98. Smith M.S., Freeman M.E., Neill J.D. The control of progesterone secretion during the estrous cycle and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated with rescue of the corpus luteum of pseudopregnancy. Endocrinology 1975, 96:219-226.
99. Green A.D., Barr A.M., Galea L.A. Role of estradiol withdrawal in 'anhedonic' sucrose consumption: a model of postpartum depression. Physiology and Behavior 2009, 97:259-265.
100. Beckley E.H., Scibelli A.C., Finn D.A. Progesterone receptor antagonist CDB-4124 increases depression-like behavior in mice without affecting locomotor ability. Psychoneuroendocrinology 2011, 36:824-833.
101. Schneider T., Popik P. Increased depressive-like traits in an animal model of premenstrual irritability. Hormones and Behavior 2006, 51:142-148.
102. Bukulmez O., Al A., Gurdal H., Yarali H., Ulug B., Gurgan T. Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: a prospective randomized trial. Fertility and Sterility 2001, 75:737-743.
103. Wihlbäck A.C., Sundström Poromaa I., Bixo M., Allard P., Mjörndal T., Spigset O. Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding. Psychoneuroendocrinology 2004, 29:757-766.
104. Biegon A., Bercovitz H., Samuel D. Serotonin receptor concentration during the estrous cycle of the rat. Brain Research 1980, 187:221-225.
105. Nishizawa S., Benkelfat C., Young S.N., Leyton M., Mzengeza S., de Montigny C., et al. Differences between males and females in rates of serotonin synthesis in human brain. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:5308-5313.
106. Kaura V., Ingram C.D., Gartside S.E., Young A.H., Judge S.J. The progesterone metabolite allopregnanolone potentiates GABAA receptor-mediated inhibition of 5-HT neuronal activity. European Neuropsychopharmacology 2007, 17:108-115.
107. Freeman E.W. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs 2004, 18:453-468.
108. Pearlstein T., Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. Journal of Psychiatry and Neuroscience 2008, 33:291-301.
109. Schneider T, Popik P. An animal model of premenstrual dysphoric disorder sensitive to antidepressants. Current protocols in neuroscience/editorial board, Jacqueline N Crawley [et al]. 2009;Chapter 9:Unit 9 31.
110. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology and Therapeutics 2006, 110:135-370.
111. Martínez-Mota La, Fernández-Guasti A. Testosterone-dependent antidepressant-like effect of noradrenergic but not of serotonergic drugs. Pharmacology Biochemistry and Behavior 2004, 78:711-718.
112. Lu N.Z., Eshleman A.J., Janowsky A., Bethea C.L. Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques. Molecular Psychiatry 2003, 8:353-360.
113. Katona C., Peveler R., Dowrick C., Wessely S., Feinmann C., Gask L., et al. Pain symptoms in depression: definition and clinical significance. Clinical Medicine 2005, 5:390-395.